Form 4: Immunovant Executive Sells Shares to Cover Tax Obligations

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On October 16, 2024, Mark S. Levine, the Chief Legal Officer of Immunovant, Inc., sold 2,860 shares of common stock at a weighted average price of $28.79.
• The sale was mandated by Immunovant to cover tax withholding obligations associated with the vesting of 5,479 restricted stock units (RSUs) on October 12, 2024, which were part of a grant of 87,664 RSUs on April 12, 2023.
• Following the transaction, Levine directly owns 327,239 shares of Immunovant common stock.
• The shares were sold in multiple transactions with prices ranging from $28.31 to $29.14 per share.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and tax obligations, and doesn't necessarily indicate positive or negative sentiment about the company's prospects.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax planning. The 'sell to cover' mechanism is a standard practice to manage tax obligations associated with equity compensation.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units (RSUs) as a way to align management's interests with those of shareholders.
• The 'sell to cover' strategy is a common method used by executives to meet their tax obligations when RSUs vest.
• Companies like Regeneron, Amgen, and Biogen also utilize similar equity compensation strategies for their executives.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations related to executive compensation.

Key Dates